FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 君百延集團控股有限公司 （於開曼群島註冊成立的有限公司） 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08372 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.01 HKD | | 80,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.01 HKD | | 80,000,000 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 君百延集團控股有限公司 （於開曼群島註冊成立的有限公司） I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08372 | 說明 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 8,000,000,000 | HKD | | 0.01 HKD | | 80,000,000 | | 增加 / 減少 (-) | | | 0 | | HKD | | 0 | | 本月底結存 | | 8,000,000,000 | HKD | | 0.01 HKD | | 80,000,000 | 本月底法定/註冊股本總額： HKD 80,000,000 第 1 頁 ...

公司法（經修訂） 獲豁免股份有限公司 GRAND BRILLIANCE GROUP HOLDINGS LIMITED 君百延集團控股有限公司 的 第三次經修訂及經重列 組織章程細則 （透過於2025 年9 月5 日舉行的股東大會上通過 的特別決議案採納） （本公司組織章程細則應以英文本為準，此中文譯本只供參考。） | 表A 1 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 詮釋 2 | | | | | | | | 股本 3 | | | | | | | | 更改股本 4–7 | | | | | | | | 股份權利 8–9 | | | | | | | | 變更權利 10–11 | | | | | | | | 股份 12–15 | | | | | | | | 股票 16–21 | | | | | | | | 留置權 22–24 | | | | | | | | 催繳股款 25–33 | | | | | | | | 沒收股份 34–42 | | | | | | | | 股東名冊 43–44 | | | | | | | | 記錄日期 | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 GRAND BRILLIANCE GROUP HOLDINGS LIMITED 君百延集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：8372） 於 2025 年 9 月 5 日舉行之股東週年大會投票結果 董事會欣然宣佈，日期為 2025 年 7 月 21 日之股東週年大會（「股東週年大會」）通告所 載全部決議案均已於 2025 年 9 月 5 日舉行之股東週年大會上獲股東以投票表決方式正式通 過。 茲提述君百延集團控股有限公司（「本公司」）日期為 2025 年 7 月 21 日之通函（「該 通函」），內容有關（其中包括）(i)授予董事發行授權；(ii)授予董事購回授權；(iii)重選 退任董事; 及(iv)接納本公司第三次經修訂及經重列的新組織章程細則。除另有所指外， 本公告所用詞彙與該通函所界定者具有相同涵義。 股東週年大會投票結果 董事會欣然宣佈，日期為 2025 年 7 月 21 ...

FF301 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08372 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.01 HKD | | 80,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.01 HKD | | 80,000,000 | 本月底法定/註冊股本總額： HKD 80,000,000 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 君百延集團控股有限公司 （於開曼群島註冊成立的有限公司） 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08372 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.01 | HKD | | 80,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.01 | HKD ...

香港聯合交易所有限公司（「香港聯交所」）GEM的特色 GEM的定位乃為相比起其他在香港聯交所上市的公司帶有較高投資風險的中小型公司提供一個上市的市場。有意投資人 士應瞭解投資該等公司的潛在風險，並應經過審慎周詳考慮後方作出投資決定。GEM的較高風險及其他特色表示GEM 較適合專業及其他資深投資者。 由於GEM上市公司的新興性質使然，在GEM買賣的證券可能會較於香港聯交所主板買賣的證券容易受到市場波動的影 響。在GEM買賣的證券亦不保證會有高流通量的市場。 香港交易及結算所有限公司及香港聯交所對本報告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告（君百延集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」或「我們」）各董事（「董事」）願就此共同及個 別承擔全部責任）乃遵照香港聯交所GEM證券上市規則（「GEM上市規則」）提供有關本集團的資料。各董事經作出一切合 理查詢後確認，就彼等所深知及確信：(1)本報告所載資料在各重大方面均屬準確及完整，並無誤導及欺詐成分；(2)本報 告並無遺漏其他事實，致使 ...

Financial Performance - The total revenue for the year ended March 31, 2025, was HKD 94,448,000, an increase of 15.3% compared to HKD 81,903,000 for the year ended March 31, 2024[6] - Gross profit for the year was HKD 45,722,000, representing a gross margin of approximately 48.4%[6] - The net profit for the year was HKD 9,191,000, up 18.1% from HKD 7,790,000 in the previous year[6] - Basic earnings per share increased to HKD 1.18 from HKD 0.98, reflecting a growth of 20.4%[6] - The group generated revenue of HKD 94,292,000 in 2025, an increase from HKD 81,747,000 in 2024, representing a growth of approximately 15.5%[22] - The pre-tax profit before income tax reached HKD 9,460,000 in 2025, an increase from HKD 7,855,000 in 2024, representing a growth of approximately 20.4%[30] - The group reported a net profit of approximately HKD 9,200,000 for the fiscal year ending March 31, 2025, an increase of about HKD 1,400,000 from HKD 7,800,000 in the previous year[50] Revenue Breakdown - Revenue from medical equipment sales reached HKD 31,657,000 in 2025, significantly up from HKD 22,899,000 in 2024, marking an increase of about 38.3%[22] - The total revenue from medical consumables was HKD 58,646,000 in 2025, up from HKD 54,985,000 in 2024, indicating an increase of approximately 4.8%[22] - The group reported a total of HKD 2,317,000 in revenue from maintenance services in 2025, compared to HKD 2,107,000 in 2024, reflecting a growth of approximately 10%[22] - Major customer A contributed HKD 18,608,000 to total revenue in 2025, while customer B contributed HKD 9,743,000, down from HKD 10,453,000 in 2024[21] Expenses and Costs - Selling and distribution expenses rose to HKD 1,397,000 from HKD 1,319,000, indicating a 5.9% increase[6] - Administrative and other operating expenses increased to HKD 37,785,000 from HKD 35,354,000, a rise of 6.9%[6] - Research and development expenses were HKD 3,926,000 in 2025, slightly down from HKD 4,080,000 in 2024, showing a decrease of about 3.8%[26] - The total employee costs, including directors' remuneration, amounted to HKD 24,031,000 in 2025, up from HKD 21,165,000 in 2024, representing an increase of about 13.5%[26] Assets and Liabilities - Total assets increased to HKD 121,640,000 from HKD 104,195,000, representing a growth of approximately 16.7% year-over-year[7] - Current assets rose to HKD 60,235,000 compared to HKD 59,988,000, indicating a slight increase of 2.1%[7] - Total liabilities increased to HKD 18,695,000 from HKD 11,219,000, reflecting a significant rise of approximately 66.5%[7] - Net current assets improved to HKD 102,945,000 from HKD 92,976,000, marking an increase of about 10.6%[7] - Equity attributable to owners of the company rose to HKD 110,786,000 from HKD 103,326,000, a growth of approximately 7.4%[7] Financial Reporting Standards - The revised Hong Kong Financial Reporting Standards will take effect on April 1, 2024, with no significant impact on the group's consolidated financial statements[13] - The group intends to adopt new and revised Hong Kong Financial Reporting Standards upon their effective date, which are expected to have no major impact on the group's performance and financial position[16] - The group is currently analyzing the new regulations and assessing the impact of Hong Kong Financial Reporting Standard No. 18 on its consolidated financial statements[17] - The group expects that the adoption of the revised standards will not have a significant impact on its consolidated financial statements[16] Corporate Governance - The group has adopted the GEM Listing Rules and has complied with all governance code provisions except for C.2.1, which states that the roles of the chairman and CEO should be separated[70] - The board believes in its independence and effectiveness, supported by a diverse background and expertise of its directors, along with established independent checks and balances[71] - The audit committee consists of two independent non-executive directors and one non-executive director, ensuring compliance with GEM Listing Rules[81] - The group's financial performance for the year ending March 31, 2025, has been reviewed by the audit committee[81] Future Outlook - The company plans to continue expanding its market presence and developing new products in the upcoming fiscal year[5] - Future guidance indicates a focus on improving operational efficiency and enhancing shareholder value[5] - The group is optimistic about the healthcare sector due to the increasing elderly population and rising health awareness among Hong Kong citizens[44] Miscellaneous - The company declared an interim dividend of HKD 2,000,000 for 2025, consistent with the HKD 2,000,000 declared in 2024[29] - The company has no outstanding contributions to defined contribution retirement plans as of March 31, 2025, which is consistent with the previous year[26] - The company has not engaged in any buybacks or sales of its listed securities during the year[68] - The company made a donation of approximately HKD 900,000 during the year[79]

Financial Performance - For the six months ended September 30, 2024, the group reported revenue of HKD 41,688,000, a slight increase of 0.93% compared to HKD 41,305,000 for the same period in 2023[3] - Gross profit for the same period was HKD 20,393,000, representing a gross margin of approximately 48.9%[3] - The net profit attributable to equity shareholders for the period was HKD 3,439,000, compared to a loss of HKD 87,000 in the previous year[3] - Basic and diluted earnings per share for the period were HKD 0.42, reflecting a significant improvement from the previous year[3] - Revenue from medical consumables reached HKD 30,014,000, up from HKD 26,497,000 in 2023, indicating a growth of about 13.5%[28] - The company reported a total of HKD 2,348,000 in other income for the six months ended September 30, 2024, compared to HKD 997,000 in 2023, reflecting a significant increase of approximately 135.5%[30] - The company's profit for the six months ended September 30, 2024, rose by approximately HKD 600,000 to HKD 3,400,000, attributed to government subsidies received amounting to approximately HKD 1,550,000[65] Assets and Liabilities - Total assets as of September 30, 2024, were HKD 103,793,000, slightly down from HKD 104,195,000 as of March 31, 2024[5] - The group’s total liabilities decreased to HKD 8,985,000 from HKD 11,219,000, indicating improved financial stability[7] - The company’s equity attributable to shareholders increased to HKD 104,765,000 from HKD 103,326,000, showing a growth in shareholder value[7] - The company's total liabilities as of September 30, 2024, were HKD 20,266,000, compared to HKD 18,203,000 as of March 31, 2024, indicating an increase of approximately 11.3%[45] - Current liabilities decreased to approximately HKD 9 million from HKD 11.2 million as of March 31, 2024[67] Cash Flow and Management - The net cash generated from operating activities for the six months ended September 30, 2024, was HKD 623,000, compared to a net cash used of HKD 2,764,000 in the same period of 2023[12] - Cash and cash equivalents at the end of the period were HKD 57,884,000, compared to HKD 52,807,000 at the end of the same period in 2023, showing an increase of about 9.8%[12] - The company's total cash and cash equivalents decreased by HKD 2,104,000 during the period, compared to a decrease of HKD 8,278,000 in the same period of 2023, reflecting improved cash flow management[12] - The financing cash outflow for the repayment of lease liabilities was HKD 1,495,000, a decrease from HKD 2,051,000 in the previous year, indicating improved cash management[12] Dividends and Shareholder Information - The company has maintained a stable dividend policy, with a declared dividend of HKD 3,200,000 during the reporting period[10] - The company did not declare an interim dividend for the six months ended September 30, 2024, consistent with the previous year[39] - No interim dividend was declared for the six months ended September 30, 2024, consistent with the previous year[66] - The company reported a total of 8,000,000,000 authorized shares, with 800,000,000 shares issued and fully paid as of September 30, 2024[54] - The number of share options available for grant under the share option scheme increased to 71,940,000 shares, representing 8.99% of the total issued share capital as of September 30, 2024[55] Research and Development - Research and development expenses for the six months ended September 30, 2024, were approximately HKD 1,909,000, up from HKD 1,534,000 in the same period of 2023, indicating a growth of about 24.5%[35] Corporate Governance and Compliance - The company has adopted the corporate governance code and complied with all provisions, with some exceptions noted[90] - The roles of the chairman and CEO are held by the same individual, Ms. Huang, who is responsible for overall strategy and major decisions[92] - The audit committee, established on March 1, 2018, consists of two independent non-executive directors and one non-executive director, ensuring proper oversight[93] - The audit committee reviewed the unaudited consolidated financial statements for the six months ending September 30, 2024, confirming compliance with applicable accounting standards[93] Market Outlook and Strategy - The group plans to continue exploring market expansion opportunities and enhancing product offerings in the upcoming periods[2] - The company maintains an optimistic outlook for the healthcare sector, driven by an aging population and increasing health awareness among Hong Kong citizens[59] - The company plans to further diversify its product offerings and enhance customer service to strengthen its position as a one-stop medical instrument solution provider[59] Risk Management - The company is closely monitoring foreign exchange risks, particularly with transactions settled in HKD, USD, or EUR, and is considering hedging measures[75]

Financial Performance - For the six months ended September 30, 2024, the company reported total revenue of HKD 41,688,000, an increase of 0.93% compared to HKD 41,305,000 for the same period in 2023[7] - The gross profit for the same period was HKD 20,393,000, reflecting a gross margin of approximately 48.9%[7] - The net profit attributable to equity shareholders for the six months was HKD 3,439,000, compared to a loss of HKD 87,000 in the previous year[7] - Basic and diluted earnings per share for the period were HKD 0.42, compared to HKD 0.00 in the same period last year[7] - The group reported a profit attributable to owners of HKD 3,439,000 for the six months ended September 30, 2024, up from HKD 2,846,000 in 2023, marking a growth of 20.8%[45] - The group’s profit increased by approximately HKD 600,000 from HKD 2,800,000 for the six months ended September 30, 2023, to HKD 3,400,000 for the same period in 2024, primarily due to government subsidies received[69] Revenue Breakdown - The group's revenue from medical consumables increased to HKD 30,014,000 in 2024 from HKD 26,497,000 in 2023, representing a growth of 18.9%[32] - Revenue from medical equipment decreased to HKD 9,677,000 in 2024 from HKD 12,811,000 in 2023, a decline of 24.5%[32] - Total revenue for the group was HKD 41,688,000 in 2024, compared to HKD 41,305,000 in 2023, reflecting a slight increase of 0.9%[32] Assets and Liabilities - Total assets as of September 30, 2024, were HKD 103,793,000, slightly down from HKD 104,195,000 as of March 31, 2024[9] - As of September 30, 2024, the company's total assets minus current liabilities amounted to HKD 107,144,000, an increase from HKD 103,276,000 as of March 31, 2024, representing a growth of 3.4%[11] - The company's non-current liabilities, including lease liabilities, increased to HKD 2,516,000 as of September 30, 2024, compared to no non-current lease liabilities reported as of March 31, 2024[11] - Trade receivables decreased from HKD 15,414,000 as of March 31, 2024, to HKD 13,232,000 as of September 30, 2024, representing a decline of approximately 14.2%[49] - The net trade receivables after impairment provisions were HKD 11,814,000 as of September 30, 2024, down from HKD 13,943,000 as of March 31, 2024, indicating a decrease of about 15.3%[49] Cash Flow - The net cash from operating activities for the six months ended September 30, 2024, was HKD 623,000, compared to a cash outflow of HKD 2,764,000 for the same period in 2023[16] - The cash and cash equivalents at the end of the reporting period were HKD 57,884,000, a decrease from HKD 61,085,000 at the beginning of the period, representing a decline of 5.5%[16] - The company experienced a net cash outflow of HKD 2,104,000 in cash and cash equivalents during the reporting period, compared to a larger outflow of HKD 8,278,000 in the previous year[16] Corporate Governance - The company has confirmed that all information provided in the report is accurate and complete, with no misleading or fraudulent elements[6] - The board of directors is committed to ensuring compliance with GEM listing rules and has undertaken reasonable inquiries to verify the report's contents[6] - The company has complied with the GEM Listing Rules regarding the "Trading Musts" standards, with no violations reported by directors or employees[92] - The audit committee, established on March 1, 2018, consists of two independent non-executive directors and one non-executive director, ensuring compliance with applicable accounting standards[97] - The company has maintained a governance structure that separates the roles of the chairman and CEO, although both roles are currently held by Ms. Huang[96] Shareholder Information - As of September 30, 2024, the company has a significant shareholder, B&A Success, holding 568,028,001 shares, representing 71.00% of the total equity[89] - Dr. Miao Yan Shun, spouse of Ms. Huang, is deemed to have the same equity interest as Ms. Huang, also holding 568,028,001 shares, equating to 71.00%[88] - Mr. Zhao Wen Wei holds 9,620,000 shares in the company, which accounts for 1.20% of the total equity[89] Employee and Operational Insights - The group employed 50 staff members as of September 30, 2024, with employee costs amounting to approximately HKD 10,300,000, an increase from HKD 9,400,000 for the same period in 2023[80] - Administrative and other operating expenses rose by approximately HKD 600,000 or 3.6%, from about HKD 16,200,000 for the six months ended September 30, 2023, to about HKD 16,800,000 for the same period in 2024[67] Future Outlook - The group remains optimistic about the healthcare industry due to the growing elderly population and increasing health awareness among Hong Kong citizens[63] - The group is seeking suitable investment opportunities to diversify its business and enhance returns for shareholders[63]